Tag : LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)

CONFERENCE UPDATE

Early initiation of luspatercept derives greater benefit in ESA-naive TD LR-MDS: Post-hoc analysis of the phase 3 COMMANDS trial
Early initiation of luspatercept outperformed epoetin alfa in erythropoiesis-stimulating agent (ESA)-naïve, transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LRMDS), achieving higher red blood celltransfusion independence (RBC-TI) ≥12-week rates and higher erythroid hematologic improvement (HI-E). The benefit was greatest in less advanced disease, with longer and more durable responses.